Anti-angiogenesis in colorectal cancer therapy

Cancer Sci. 2024 Mar;115(3):734-751. doi: 10.1111/cas.16063. Epub 2024 Jan 17.

Abstract

The morbidity of colorectal cancer (CRC) has risen to third place among malignant tumors worldwide. In addition, CRC is a common cancer in China whose incidence increases annually. Angiogenesis plays an important role in the development of tumors because it can bring the nutrients that cancer cells need and take away metabolic waste. Various mechanisms are involved in the formation of neovascularization, and vascular endothelial growth factor is a key mediator. Meanwhile, angiogenesis inhibitors and drug resistance (DR) are challenges to consider when formulating treatment strategies for patients with different conditions. Thus, this review will discuss the molecules, signaling pathways, microenvironment, treatment, and DR of angiogenesis in CRC.

Keywords: VEGF; angiogenesis; colorectal cancer; drug resistance; therapy.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • China
  • Colorectal Neoplasms* / pathology
  • Humans
  • Neovascularization, Pathologic / pathology
  • Signal Transduction
  • Tumor Microenvironment
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Vascular Endothelial Growth Factor A
  • Angiogenesis Inhibitors